Advances in targeted therapies for hematological malignancies for exploring novel molecular targets, synergistic combination approaches, and emerging mechanisms of drug resistance to enhance precision oncology and improve patient outcomes

Kinase inhibitors, immunotherapies, and epigenetic agents are some of the targeted therapies of hematologic malignancies that exploit biological weaknesses. Even with mechanisms of resistance such as mutations and pathway alterations that require a change in the treatment strategy, combination therapy enhances effectiveness. Hematologic neoplasias, leukemia, lymphoma, and myeloma are still a major issue, and there is a need for new therapies. New drugs like menin inhibitors have been achieved through new targets like lysine (K)-specific methyltransferase 2A and nucleophosmin 1 mutations in acute myeloid leukemia. Protease and phosphoinositide 3-kinase inhibitors are some of the synergistic methods which help to counter drug resistance. Bispecific antibodies such as glofitamab enhance accessibility, whereas chimeric antigen receptor T (CAR-T) and CAR-natural killer therapy are strong alternatives. Checkpoint inhibitors, however, are immunomodulatory drugs that maximize immune response and are also being researched to be administered with combination therapy. Precision medicine advances are constantly enhancing treatment modalities, raising survival, and reducing resistance in hematologic neoplasms. Patient outcomes have been transformed by targeted treatments like immune checkpoint inhibitors, CAR-T cells, and molecular inhibitors. Long-term follow-up continues to be essential to maximize outcomes.